PMCF under MDR: from regulatory obligation to competitive advantage
In many medical device companies, Post-Market Clinical Follow-up (PMCF) is still seen as a burden — a bureaucratic requirement introduced by the EU MDR (EU 2017/745) that adds cost and pressure to already overloaded regulatory teams. That view is increasingly short-sighted.Companies that treat PMCF purely as compliance are missing a significant strategic opportunity. The MDR…
Real-World Evidence and MDR: why post-market data often matters more than trials
There is a paradox in medical device research that is rarely discussed openly. The most controlled, expensive and rigorously monitored method of generating clinical evidence (the interventional trial) often produces evidence that becomes less useful once the device enters real clinical practice. Clinical trials typically ask: Does the device work under optimal conditions, with selected…
Innovative medical device in 2026: how to build an evidence strategy that holds…without drowning in rework
There’s a sentence we hear often from founders, Clinical Affairs and Regulatory teams: “We have a strong device, but we’re afraid of losing time.” Not time spent working.Time lost to rework, the kind that appears halfway through a study, when you realize it started… but wasn’t solid enough. Studies don’t fail because there’s a lack…
Risk-based means protecting what matters most
In clinical research, risk-based approaches are everywhere: they appear in protocols, monitoring plans, and quality systems. But there is a growing misunderstanding. Many organizations treat risk-based as a justification to reduce activities: fewer checks, lighter processes, less on-site monitoring. The goal is often simple: cut time and cost. Technically and regulatorily, this interpretation is wrong.…
Digital twins in Clinical trials: a new way of designing studies
In the past year, Digital twin has become one of the most overused terms in healthcare innovation. It appears in conference slides, CRO strategy decks, and investor presentations, often described as a virtual copy of a patient, ready to be tested like an avatar in a simulation. But the reality is less cinematic and far…
MDR 2025: What’s Really Changing and How to Prepare Now
The MDR deadline extension is not a pause. It’s a strategic opportunity – but only if you act early. Back in early 2024, the European Commission granted more time for companies to align with Regulation (EU) 2017/745 (MDR) – particularly concerning legacy devices. While many manufacturers welcomed the extra breathing room, be careful: more time doesn’t mean fewer…
GCP R3 – Episode 1: What you need to know (Especially if you work in MedTech)
GCP R3: GCP is evolving, are you? The ICH has released the E6(R3) revision of Good Clinical Practice (GCP), and it marks a turning point. With this update, the rules of clinical evidence have changed, and if you’re working on medical devices, SaMD or digital health, you’re in the game now too. No need to worry, here’s a…
MDR – Racing Against Time for Your CE Mark
The extension is here, but it’s not a safety net. Learn how to move fast, stay compliant, and protect your market share. With Regulation (EU) 2023/607, the European Commission has introduced a critical extension to MDR deadlines for legacy devices certified under the previous MDD (Directive 93/42/EEC). It’s a valuable opportunity—but not an excuse to delay.…
AI and Automated Systems in Clinical Research: Support, Limits, and Why the CRA Cannot Be Replaced
Artificial Intelligence (AI) and automated systems are transforming the clinical research sector, improving data collection and analysis, optimizing decision-making processes, and reducing study time and costs. However, while these technologies offer valuable support, it is essential to understand that they cannot replace the Clinical Research Associate (CRA) nor human judgment. At We4CR, we use AI…
How to Streamline Ethics Committees for Faster Clinical Research in Italy
Clinical research is a fundamental pillar for the progress of medicine and the development of new therapies. The role of the Ethics Committees (ECs), independent bodies responsible for evaluating and approving trials, is a crucial element in ensuring ethical and safe clinical trials, ensuring that participants’ rights, safety and well-being are protected. In the past, the fragmentation…
